Breaking News

Polyplus Expands LipidBrick Library to Optimize LNP Formulation

Additional cationic lipids broaden the scope of LNP usage to treat various diseases.

Polyplus, an upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, has expanded the LipidBrick Library with several new proprietary cationic lipids for lipid nanoparticle (LNP) formulation in mRNA therapeutic and vaccine development. Building forward from LipidBrick IM21.7c and off-the shelf in vivo-jetRNA+transfection reagent, these additional cationic lipids broaden the scope of LNP usage to treat various diseases. Accordin...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters